Putting Patients First
We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”
We are advancing an innovative, high-value product portfolio for patients globally.
Passion with Purpose
We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.
August 9, 2022
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular CancerRead more
July 14, 2022
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCCRead more
July 6, 2022
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA TherapiesRead more
June 30, 2022